Skip to search formSkip to main contentSkip to account menu

varespladib methyl

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Introduction: Cardiovascular disease is the most common cause of morbidity and mortality worldwide. Inflammation is responsible… 
Review
2012
Review
2012
Certain members of the phospholipase A(2) superfamily of enzymes have established causal involvement in atherosclerosis, thus at… 
Highly Cited
2012
Highly Cited
2012
BackgroundThe action of secretory phospholipase A2 (sPLA2) on lipoproteins may render them more susceptible to oxidation, thereby… 
Highly Cited
2011
Highly Cited
2011
AIMS To investigate the effects of secretory phospholipase A2 (sPLA(2)) inhibition on plasma lipoproteins. Secretory… 
2011
2011
PurposeSecretory phospholipase A2 group IIA (sPLA2−IIA) concentration and activity are associated with increased risk of… 
2011
2011
Secretory phospholipase A(2) (sPLA(2)) represents a family of isoenzymes that participate in lipoprotein and inflammatory… 
Review
2010
Review
2010
Importance of the field: The high risk of recurrent cardiovascular events amongst patients with cardiovascular disease receiving… 
Review
2010
Review
2010
  • R. Rosenson
  • Current Opinion in Lipidology
  • 2010
  • Corpus ID: 542286
Purpose of review Selective inhibitors of secretory phospholipase A2 and lipoprotein-associated phospholipase A2 are potential… 
2009
2009
Varespladib methyl is an oral secretory phospholipase A2 inhibitor that is being developed by Anthera Pharmaceuticals Inc for the…